Blueprint Medicines Co. (NASDAQ:BPMC) to Post Q2 2026 Earnings of $0.33 Per Share, Zacks Research Forecasts

Blueprint Medicines Co. (NASDAQ:BPMC) – Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Blueprint Medicines in a report released on Monday, September 16th. Zacks Research analyst A. Chakraborty now anticipates that the biotechnology company will post earnings of $0.33 per share for the quarter, up from their previous forecast of $0.31. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The firm had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. During the same period in the previous year, the company posted ($2.19) EPS. The business’s revenue for the quarter was up 139.9% compared to the same quarter last year.

A number of other equities research analysts have also weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $130.00 price objective on shares of Blueprint Medicines in a report on Thursday, August 1st. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Friday, June 7th. Barclays upped their target price on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, July 29th. Oppenheimer lifted their price objective on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, July 8th. Finally, Morgan Stanley increased their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines has an average rating of “Moderate Buy” and a consensus target price of $120.00.

Blueprint Medicines Stock Up 3.3 %

Blueprint Medicines stock opened at $89.33 on Thursday. The stock has a market capitalization of $5.59 billion, a price-to-earnings ratio of -18.57 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The business has a fifty day moving average price of $99.35 and a 200-day moving average price of $99.08. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $121.90.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors have recently bought and sold shares of BPMC. Triad Wealth Partners LLC purchased a new position in shares of Blueprint Medicines in the second quarter valued at approximately $27,000. Covestor Ltd lifted its holdings in Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after buying an additional 291 shares in the last quarter. Headlands Technologies LLC boosted its position in Blueprint Medicines by 105.2% in the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 342 shares during the period. Natixis purchased a new position in Blueprint Medicines in the 1st quarter valued at approximately $73,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Blueprint Medicines in the fourth quarter worth $95,000.

Insiders Place Their Bets

In other news, insider Debra Durso-Bumpus sold 74,034 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $104.19, for a total transaction of $7,713,602.46. Following the transaction, the insider now owns 43,763 shares of the company’s stock, valued at approximately $4,559,666.97. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $104.19, for a total transaction of $7,713,602.46. Following the sale, the insider now owns 43,763 shares of the company’s stock, valued at approximately $4,559,666.97. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the transaction, the insider now owns 34,729 shares in the company, valued at $3,236,395.51. The disclosure for this sale can be found here. Insiders sold 128,947 shares of company stock valued at $13,065,852 in the last three months. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.